컴패스 패스웨이즈(CMPS)는 NASDAQ에 상장된 Healthcare · Medical Care Facilities 기업입니다. 현재가 $15.29 (+1.93%), 시가총액 $1.40B, 52주 최저~최고 $2.35 ~ $10.96.
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
컴패스 패스웨이즈의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
컴패스 패스웨이즈의 현재 주가는 $15.29 (+1.93%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
컴패스 패스웨이즈의 시가총액은 약 $1.40B입니다.
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phas